All Studies Meta Analysis Recent:

Investigating efficacy of colchicine plus phenolic monoterpenes fraction as a potential treatment for patients diagnosed with COVID-19: A randomized controlled parallel clinical trial

Vaziri et al., Heliyon, doi:10.1016/j.heliyon.2024.e27373, NCT04392141

Mar 2024

Post
Facebook

Source PDF All Meta

Colchicine for COVID-19

5th treatment shown to reduce risk in September 2020

^*, now known with p = 0.00000018 from 53 studies.

Lower risk for mortality, ICU admission, hospitalization, and recovery.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,100+ studies for 60+ treatments. c19early.org

RCT 179 hospitalized COVID-19 patients showing lower mortality, ICU admission, and hospitalization duration with colchicine plus phenolic monoterpenes compared to standard care alone. The intervention group received 0.8 mg/day colchicine and 45 mg/day phenolic monoterpenes extracted from nigella sativa and Trachyspermum ammi in addition to standard care (lopinavir/ritonavir). No serious side effects were reported. Baseline SpO₂ was significantly lower in the control group, although there was no significant difference in severity according to NIH guidelines.

This study is excluded in the after exclusion results of meta analysis: randomization resulted in significant baseline differences that were not adjusted for.

Important missing comments or errors? Let us know.

Study covers nigella sativa and colchicine.

risk of death, 81.2% lower, RR 0.19, p = 0.03, treatment 2 of 108 (1.9%), control 7 of 71 (9.9%), NNT 12, after 14 day followup.

risk of death, 89.0% lower, RR 0.11, p = 0.02, treatment 1 of 108 (0.9%), control 6 of 71 (8.5%), NNT 13, in hospital.

risk of ICU admission, 86.9% lower, RR 0.13, p = 0.002, treatment 2 of 108 (1.9%), control 10 of 71 (14.1%), NNT 8.2.

hospitalization time, 34.7% lower, relative time 0.65, p < 0.001, treatment mean 4.17 (±1.34) n=108, control mean 6.39 (±2.59) n=71.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Vaziri et al., 6 Mar 2024, Randomized Controlled Trial, Iran, peer-reviewed, mean age 54.2, 11 authors, study period April 2020 - December 2020, this trial uses multiple treatments in the treatment arm (combined with phenolic monoterpenes) - results of individual treatments may vary, trial NCT04392141 (history). Contact: amostafaie@kums.ac.ir.

This Paper Colchicine All

Investigating efficacy of colchicine plus phenolic monoterpenes fraction as a potential treatment for patients diagnosed with COVID-19: A randomized controlled parallel clinical trial

Siavash Vaziri, Alireza Janbakhsh, Mohammad Hossein Zamanian, Yadollah Shakiba, Shayan Mostafaei, Amir Hossein Norooznezhad, Kamran Mansouri, Ph.D Ahmad Bagheri, Farhad Abdali, Kavyan Fatahpour, Ali Mostafaie

Heliyon, doi:10.1016/j.heliyon.2024.e27373

Background: COVID-19 now is a serious concern for the world healthcare system. This study aimed to investigate possible therapeutic effect of colchicine and phenolic monoterpenes accompanied by standard care of treatment (SCT) in patients diagnosed with COVID-19. Methods: In this randomized controlled parallel clinical trial, a total number of 179 (of 200) patients with confirmed COVID-19 were enrolled according to the inclusion and exclusion criteria. The patients were allocated by simple randomization method into two groups control (receiving SCT with 71 patients) and intervention (receiving SCT plus colchicine and phenolic monoterpenes with 107 patients). The mortality ratio during hospitalization as well as a 2-week follow-up, ICU admission rate, and hospitalization duration were assessed as main outcomes. Results: The mortality ratio was 0.9% (1/108) and 8.45% (6/71) in the intervention and the control groups (p-value= 0.035) respectively, these ratios after a 14-day follow-up were 1.85% (2/108), and 9.85 (7/71) respectively (p-value= 0.031). Also, the ICU admission was significantly lower (p-value= 0.006) in the intervention group 2/108 (1.85%) compared with controls 10/71 (14.08%). Moreover, the duration of hospitalization followed a similar pattern to ICU admission with 4.17 ± 1.34 vs. 6.39 ± 2.59 days in the intervention and control groups respectively (p-value< 0.001). Furthermore, no significant side effect was found between the groups. Conclusion: According to the results, the combination of colchicine plus phenolic monoterpenes could be an additive treatment for the SCT. The authors strongly recommend further trials on this combination with other SCTs.

Conflict of interest Prof. Ali Mostafaie and Mr. Kavyan Fattahipour are employees of Zist Tolid Razi Co. Other authors declare no actual or potential conflict of interest. J o u r n a l P r e -p r o o f

References

Ang, Song, Lee, Lee, Herbal Medicine for the Treatment of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis of Randomized Controlled Trials, J Clin Med

De Las Heras, Martín Giménez, Ferder, Manucha, Lahera, Implications of Oxidative Stress and Potential Role of Mitochondrial Dysfunction in COVID-19: Therapeutic Effects of Vitamin D, Antioxidants

Deftereos, Giannopoulos, Vrachatis, Siasos, Giotaki et al., Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial, JAMA New Open

Hantoushzadeh, Norooznezhad, Inappropriate Antibiotic Consumption as a Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed with Coronavirus-19 Disease (COVID-19), Arch Med Res

J O U R N A L P R E, None

Koshak, Koshak, Mobeireek, Badawi, Wali et al., Nigella sativa supplementation to treat symptomatic mild COVID-19: A structured summary of a protocol for a randomised, controlled, clinical trial, Trials

Leung, Hui, Kraus, Colchicine--Update on mechanisms of action and therapeutic uses, Semin Arthritis Rheum

Libby, Lüscher, COVID-19 is, in the end, an endothelial disease, Eur Heart J

Lopes, Bonjorno, Giannini, Amaral, Menezes et al., Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial, RMD Open

Norooznezhad, Eskandarion, Akbari, Alimohammadi, Nabavian et al., Changes of Leukocytes, Neutrophils, and Lymphocytes Count and Dependent Variables in Pregnant Women with Coronavirus Disease 2019 (COVID-19) Before and After Cesarean Delivery, J Med Virol

Norooznezhad, Najafi, Riahi, Moradinazar, Shakiba et al., Primary Symptoms, Comorbidities, and Outcomes of 431 Hospitalized Patients with Confirmative RT-PCR Results for COVID-19, Am J Trop Med Hyg

Shaterzadeh-Yazdi, Noorbakhsh, Hayati, Samarghandian, Farkhondeh, Immunomodulatory and Anti-inflammatory Effects of Thymoquinone, Cardiovasc Hematol Disord Drug Targets

Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0